Navigation Links
Primary Graft Dysfunction Is Risk Factor For Lung Transplant Problem

Primary graft dysfunction, a common complication that affects up to 25 percent of lung transplant patients shortly after surgery, constitutes// a significant risk factor for later deadly bronchiolotis obliterans syndrome (BOS).

This research appears in the first issue for March 2007 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

Ramsey R. Hachem, M.D., of the Division of Pulmonary and Critical Care at Washington University School of Medicine in St. Louis, and eight associates examined the impact of primary graft dysfunction on the development of BOS in 320 lung transplant recipients.

BOS, a chronic scarring process that affects the small airways of the lungs years after transplant surgery, results in the progressive obliteration of the small airways with resulting obstructive lung disease. BOS is a leading cause of death after the one-year anniversary of a lung transplant.

“We found that primary graft dysfunction is associated with an increased risk of BOS independent of certain other risk factors, including acute rejection and community-acquired respiratory viral infections,” said Dr. Hachem.

Clinically and pathologically, primary graft dysfunction is a devastating form of acute lung injury that affects transplant patients in the first hours after they receive transplanted organs. The complication, which mimics adult respiratory distress syndrome, can be fatal for up to 50 percent of affected transplant patients.

“Among the 320 recipients studied, 161 developed BOS, with the median time to onset at close to four years,” said Dr. Hachem. “Lung transplant recipients who did not have primary graft dysfunction had significantly greater freedom from BOS than those who developed any grade of primary graft dysfunction.”

The researchers graded the severity of subjects’ primary graft dysfunction according to the International Society for Heart and Lung Transplantation (ISHLT) definition. Those who did not have primary graft dysfunction immediately after transplantation were classified grade 0, while those with more severe graft dysfunction received a 1, 2 or 3.

In their analysis, the investigators found that all grades of primary graft dysfunction were associated with a significantly increased risk of BOS. Recipients with primary graft dysfunction grade 1 had the relative risk of 1.73; those with grade 2 had a relative risk of 2.13; and those with grade 3 were 2.53 times more likely to experience the later problem.

“This association has important clinical implications and suggests that the immunosuppressive regimen should be optimized and that lung function should be monitored closely for patients who develop primary graft dysfunction,” said Dr. Hachem.

The researchers noted that additional studies are needed to further investigate the molecular mechanisms of primary graft dysfunction and its relationship to BOS.

According to the ISHLT, this area of study is becoming increasingly important, as the number of lung transplants performed in the U.S. was a record 1,815 last year. They reported that survival was 78 percent at one year, 61 percent at three years, 49 percent at five years, and 25 percent at 10 years.

Source-Newswis
SRM
'"/>




Related medicine news :

1. Shortage Of Funds In Primary Care Trust In UK
2. What Will Primary Care Look Like In England by 2015?
3. Primary Health Care MoU Signed on the Sidelines of the PBD
4. Primary Care centers to provide out patient treatment
5. Early Detection Of Primary Liver Cancer Would Save Millions Of Lives
6. Brunei Closes Primary Schools In A Bid To Contain Hand, Foot and Mouth Disease
7. Gene That Causes Metastasis of the Primary Tumor, Identified
8. IMA To Train Doctors In Primary Treatment Of HIV/AIDS
9. Primary School Children Will Be Weighed And Parents Informed If They Are Obese
10. Funding Approved for Research into Primary Health Care
11. British Teachers Concerned About Primary School kid’s Sexual Behavio
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/21/2017)... ... April 21, 2017 , ... Brady (NYSE:BRC), a ... B-595 and B-7569 vinyl label materials received certification for the ... are tested to remain intact and legible, for use on chemical drums shipped by ...
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... weeklong campaign, AWARE: A Week of Addiction and Recovery Education, from April 24 ... treating and preventing substance use disorders. , The mission of AWARE is ...
(Date:4/21/2017)... ... April 21, 2017 , ... Metrasens is honoured ... Trade, the UK’s most prestigious award for business success. The company has ... revenues and has grown by a total of 400% over the last six ...
(Date:4/21/2017)... ... April 21, 2017 , ... Westside Dental Associates ... dental care since 1985. After thirty-two years, Dr. Latner has become one of the ... my numerous clients over the years with all their dental needs,” said Dr. Latner, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
Breaking Medicine Technology: